Purkiss Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Purkiss Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-322	Closed	-$206K	–	171
2025 Q3	$206K	Buy	+322	New	+$195K	0.1%	162

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Purkiss Capital Advisors's IDXX Position: Q4 2025 in Review

Purkiss Capital Advisors sold out of Idexx Laboratories (IDXX) in Q4 2025, closing a stake of 322 shares — an estimated $206K sold.

Purkiss Capital Advisors first reported a position in IDXX in Q3 2025 and held it in 1 quarter. The position peaked at $206K in Q3 2025. 1,386 funds tracked by Wall St. Rank hold IDXX as of Q4 2025.

Purkiss Capital Advisors reported no remaining Idexx Laboratories position as of Q4 2025 after selling out during the quarter.
Purkiss Capital Advisors sold 322 Idexx Laboratories shares in Q4 2025, an estimated $206K.
Purkiss Capital Advisors first reported a position in Idexx Laboratories in Q3 2025 and held it in 1 quarter.
Purkiss Capital Advisors's Idexx Laboratories position peaked at $206K in Q3 2025.
1,386 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2025.

Based on Purkiss Capital Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.